SWM
HAE icon

SeaCrest Wealth Management’s Haemonetics HAE Stock Holding History

SeaCrest Wealth Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,000
Closed -$65K – 983
2022
Q2 		$65K Buy
+1,000
New +$59.2K 0.01% 1020

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SeaCrest Wealth Management's HAE Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Haemonetics (HAE) in Q3 2022, closing a stake of 1,000 shares — an estimated $65K sold.

SeaCrest Wealth Management first reported a position in HAE in Q2 2022 and held it in 1 quarter. The position peaked at $65K in Q2 2022. 270 funds tracked by Wall St. Rank hold HAE as of Q3 2022.

  • SeaCrest Wealth Management reported no remaining Haemonetics position as of Q3 2022 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,000 Haemonetics shares in Q3 2022, an estimated $65K.
  • SeaCrest Wealth Management first reported a position in Haemonetics in Q2 2022 and held it in 1 quarter.
  • SeaCrest Wealth Management's Haemonetics position peaked at $65K in Q2 2022.
  • 270 funds tracked by Wall St. Rank held Haemonetics as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.